ARROWHEAD PHARMACEUTICALS, INC.

(ARWR)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Arrowhead Pharmaceuticals to Invest up to $250 Million in New Facilities in Verona, Wisconsin

12/20/2021 | 10:27am EDT


© MT Newswires 2021
All news about ARROWHEAD PHARMACEUTICALS, INC.
05/24Goldman Sachs Adjusts Arrowhead Pharmaceuticals' Price Target to $66 from $90, Keeps Bu..
MT
05/13B. Riley Lowers Arrowhead Pharmaceuticals' PT to $82 from $106 to Account for Higher Re..
MT
05/12TRANSCRIPT : Arrowhead Pharmaceuticals, Inc. Presents at Bank of America 2022 Healthcare C..
CI
05/12NORTH AMERICAN MORNING BRIEFING : Stocks Seen -3-
DJ
05/11Piper Sandler Lowers Arrowhead Pharmaceuticals Price Target to $72 From $89, Maintains ..
MT
05/11Chardan Lowers Arrowhead Pharmaceuticals Price Target to $80 From $94, Maintains Buy Ra..
MT
05/11Inflation: Have we passed the peak yet?
05/11ANALYST RECOMMENDATIONS : Electronic Arts, Corning, Arrowhead Pharma, Tesla, Wynn Resorts...
05/11Baird Upgrades Arrowhead Pharmaceuticals to Outperform From Neutral, Cuts Price Target ..
MT
05/10TRANSCRIPT : Arrowhead Pharmaceuticals, Inc., Q2 2022 Earnings Call, May 10, 2022
CI
More news
Analyst Recommendations on ARROWHEAD PHARMACEUTICALS, INC.
More recommendations
Financials (USD)
Sales 2022 304 M - -
Net income 2022 -105 M - -
Net cash 2022 453 M - -
P/E ratio 2022 -30,2x
Yield 2022 -
Capitalization 3 574 M 3 574 M -
EV / Sales 2022 10,3x
EV / Sales 2023 12,6x
Nbr of Employees 329
Free-Float -
Chart ARROWHEAD PHARMACEUTICALS, INC.
Duration : Period :
Arrowhead Pharmaceuticals, Inc. Technical Analysis Chart | ARWR | US04280A1007 | MarketScreener
Technical analysis trends ARROWHEAD PHARMACEUTICALS, INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 11
Last Close Price 33,80 $
Average target price 78,08 $
Spread / Average Target 131%
EPS Revisions
Managers and Directors
Christopher Richard Anzalone President, Chief Executive Officer & Director
Kenneth Allen Myszkowski Chief Financial Officer
Douglass B. Given Chairman
Javier San Martin Chief Medical Officer
Jeff Ketelhut Vice President-Information Technology & Systems
Sector and Competitors
1st jan.Capi. (M$)
ARROWHEAD PHARMACEUTICALS, INC.-49.02%3 574
GILEAD SCIENCES, INC.-11.38%80 715
REGENERON PHARMACEUTICALS, INC.8.63%73 916
VERTEX PHARMACEUTICALS22.26%68 665
WUXI APPTEC CO., LTD.-22.20%40 017
BIONTECH SE-40.07%37 546